Living near green spaces linked to stronger bones in young children

Out of hun­dreds of po­ten­tial drugs with rare pe­di­atric dis­ease des­ig­na­tions, on­ly 7% of them have won pri­or­i­ty re­view vouch­ers from the FDA, ac­cord­ing to

SAN DIEGO — Treatment with the B-cell depleting agent obinutuzumab (Gazyva) helped patients with lupus nephritis avoid the most serious adverse outcomes, according to a